Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published research on matcha, L-theanine, and EGCG. It is informational only and is not medical advice. Not medical advice. Consult a qualified healthcare professional before changing your diet or supplement regimen, particularly if you take medications, have a liver condition, or are on anticoagulant therapy.

The question the acute attention trials do not answer

Much of the publicly circulated research on matcha and cognitive function centers on an acute-dose question: does L-theanine combined with caffeine improve attention in the hour after consumption? The answer from those trials is a qualified yes for specific attention tasks, and those findings are covered in detail in a separate article. This article is about a different question: does regular consumption of matcha — and the L-theanine and EGCG it delivers — have any relationship to how cognitive function holds over years?

The cognitive aging question draws on different research designs. Rather than randomized crossover studies measuring reaction time, it draws on Japanese cohort data tracking older adults, and on a smaller set of RCTs measuring stress biomarkers and cognitive function over weeks rather than hours. Both the cohort data and the mechanistic RCTs are suggestive and limited; neither constitutes proof of a cognitive longevity benefit. Knowing what they actually show is the relevant starting point.

EGCG and neuroprotection research: what the human evidence actually contains

EGCG (epigallocatechin gallate) is the most abundant catechin in green tea and the compound most studied for potential effects on brain aging. Matcha contains more EGCG than most green tea preparations because you consume the whole leaf rather than an infusion; analytical surveys of Japanese matcha typically find 50–80 mg of EGCG per gram of powder, making a 1–2 g serving the highest-EGCG green tea option available.

The mechanistic case for neuroprotection research rests on two properties. First, EGCG has demonstrated antioxidant activity in biological systems and has been shown to inhibit amyloid-beta fibril formation in laboratory models. Second, rodent studies have measured EGCG crossing the blood-brain barrier — a pharmacological prerequisite for direct central nervous system effects. What these findings do not establish is whether concentrations achievable through dietary or supplemental intake in humans are sufficient to produce comparable effects; the concentrations used in most preclinical studies substantially exceed what dietary consumption realistically delivers.

The human trial record for EGCG and cognitive outcomes is sparse. A crossover RCT by Mancini et al. published in Clinical Nutrition (2017) enrolled 27 healthy volunteers and tested EGCG at 135 mg (capsule form) against placebo in an acute-dose design. The EGCG arm was associated with improved working memory performance on a task battery, along with changes in frontal brain activity measured by functional MRI. The sample was small, the design was acute rather than long-term, and the finding has not been independently replicated at this writing. These results are mechanistically coherent and directionally interesting; they are not sufficient to make a clinical recommendation.

EGCG’s rapid oral metabolism is a persistent complicating factor. After ingestion, EGCG is largely converted to glucuronide and sulfate metabolites before reaching systemic circulation in meaningful concentrations. This does not mean dietary or supplemental EGCG is without effect — some downstream metabolites retain biological activity — but it does mean the dose-response relationship from food to tissue is less direct than preclinical studies suggest.

L-theanine, cortisol, and why the stress pathway matters for cognitive aging

L-theanine’s most clearly documented effect in human trials is on the stress response rather than on memory or attention directly. The cognitive aging relevance is indirect but mechanistically coherent: chronic psychological stress is associated with elevated cortisol, and sustained elevated cortisol is correlated with accelerated cognitive decline in longitudinal epidemiological data.

L-theanine is an amino acid structurally similar to glutamate and is proposed to modulate the brain’s excitatory-inhibitory balance via effects on glutamate receptor activity and GABA levels. EEG research, including Kelly et al. (Journal of Nutrition, 2008), has measured increased alpha-band oscillatory activity following L-theanine administration — a neural signature associated with relaxed wakefulness and consistent with a stress-attenuating mechanism.

A four-week randomized trial by Hidese S et al. published in Nutrients (2019) enrolled 30 healthy adults and administered 200 mg of L-theanine per day or placebo. The L-theanine group showed reduced scores on the Pittsburgh Sleep Quality Index and the State-Trait Anxiety Inventory, and improved performance on some verbal fluency and executive function measures. Thirty participants is a small sample, and self-report instruments have known limitations; the finding warrants replication before informing clinical practice. What it contributes is a plausible pathway from L-theanine’s documented stress-attenuation effect to cognitive outcomes, measured in a randomized design rather than an observational one.

The dose question matters here. The Hidese trial used 200 mg/day. A standard 2 g matcha serving provides approximately 50–90 mg of L-theanine. Reaching 200 mg/day from matcha alone would require three to four servings — a realistic daily intake for habitual matcha drinkers in Japan, but above typical Western consumption. This is where standalone L-theanine supplements offer a practical alternative.

What the Tsurugaya Project and related cohort data found

The most-cited Japanese cohort study on green tea and cognitive function is from the Tsurugaya Project, a community-based study of 1,003 adults aged 70 and above in Sendai, Yamagata Prefecture. Kuriyama S et al. published findings in the American Journal of Clinical Nutrition (2006): after adjusting for age, sex, education, and comorbidity, consumption of two or more cups of green tea per day was associated with lower odds of cognitive impairment — defined as an MMSE score below 28 — compared to consumption of three or fewer cups per week. In the fully adjusted model, the odds ratio for cognitive impairment in the highest consumption group was approximately 0.54 relative to the lowest group.

This is a cross-sectional observation, not a clinical trial. It cannot establish causal direction, and it cannot rule out unmeasured confounders. Older Japanese adults who drink more green tea may systematically differ from those who drink less in ways difficult to capture statistically — physical activity levels, overall diet quality, social engagement, health-seeking behaviors. The association is consistent and robust to adjustment for common confounders, but cohort data of this type has inherent limits.

Separate community-based studies in older Japanese populations have reported directionally consistent findings between regular green tea consumption and cognitive test performance. The pattern across these observational studies is more consistent than contradicted, but the evidence type — cross-sectional and observational — does not support efficacy claims. What it supports is the proposition that green tea consumption, as part of the broader traditional Japanese dietary pattern, is associated with better cognitive outcomes in older Japanese adults.

An important interpretive note: the Tsurugaya data is on whole tea consumption in a Japanese population eating a traditional Japanese diet. It cannot be cleanly extended to an isolated supplement taken alongside a Western diet. The association may partly or largely reflect the broader dietary pattern, rather than green tea specifically.

Comparing dose: food form versus isolated supplements

A 2 g serving of ceremonial-grade matcha delivers approximately:

• L-theanine: 50–90 mg
• EGCG: 100–160 mg
• Caffeine: 60–75 mg

The Hidese L-theanine trial used 200 mg/day; the Mancini EGCG trial used 135 mg as an isolated capsule. A 2 g matcha serving reaches the lower end of the Mancini EGCG range while delivering L-theanine below the Hidese trial dosing. For someone who wants to approximate the trial conditions more closely, isolated L-theanine capsules allow 200 mg/day without the caffeine component — particularly relevant for evening use, when the Hidese trial’s sleep quality findings are most applicable.

There is no human trial evidence that isolated EGCG or L-theanine produces equivalent outcomes to the whole-leaf food form. The Japanese cohort data is on tea consumption — the whole-leaf preparation — not on supplementation. Supplement doses allow specific targeting; food-matrix consumption approximates the exposure pattern in the observational literature.

How to source

Matcha powder (food-matrix option)

Ceremonial-grade matcha from shade-grown Japanese tea is the form with meaningful EGCG and L-theanine concentrations. Culinary-grade material is processed at higher temperatures and contains substantially less of both compounds. Amazon US carries options from Uji and Kagoshima producers, including Ippodo and Marukyu Koyamaen. Expect $25–60 for 30 g of genuine ceremonial grade; products priced substantially below that threshold are typically culinary grade or blended.

L-theanine supplements (isolated, caffeine-free)

Standalone L-theanine capsules allow dosing at 100–200 mg/day without the caffeine component. Amazon US carries Jarrow Formulas Theanine (100 mg capsules) and NOW Foods L-Theanine (100 mg and 200 mg options), both with third-party testing documentation. At 200 mg/day, this approximates the Hidese et al. 2019 trial dosing.

EGCG supplements

Isolated green tea extract standardized to ≥90% EGCG is available for those specifically targeting the catechin component. Amazon US carries options from NOW Foods, Jarrow Formulas, and Life Extension. One important dose note: isolated high-dose EGCG supplements above 400 mg/day have been linked to hepatotoxicity case reports in the adverse event literature — a risk not present at the 135 mg range studied by Mancini et al., or at EGCG doses achievable from standard matcha servings. Staying within the trial dose range is the appropriate baseline unless under physician guidance.

Who should discuss this with a clinician first

• Anyone on anticoagulant therapy — EGCG has shown platelet-inhibiting activity in laboratory models; clinical significance at food-level doses is not well characterized, but high-dose EGCG supplement use warrants clinician disclosure
• Anyone with a history of liver disease or hepatotoxic drug reactions — relevant specifically to high-dose isolated EGCG supplements, less so to matcha food form
• Anyone with thyroid conditions — high daily catechin intake may affect iron absorption timing and interact with thyroid hormone absorption; discuss regular high-dose EGCG supplement use with your endocrinologist
• Anyone taking stimulant medications or MAOIs — matcha’s caffeine content creates relevant interaction considerations
• Pregnant or breastfeeding individuals — caffeine content and limited controlled safety data for supplemental EGCG doses

The honest position on L-theanine and EGCG for cognitive aging: the Tsurugaya cohort data and the small mechanistic RCTs are directionally consistent with plausible mechanisms. The current evidence does not establish that supplementing with these compounds at commercially available doses slows cognitive aging or extends cognitive healthspan in healthy adults. What the Japanese observational literature supports is an association between habitual green tea consumption — within the context of a traditional Japanese dietary pattern — and better cognitive outcomes in older adults. The distance between that observational association and a supplement recommendation is real, and worth carrying into any purchasing decision.

For the acute attention angle and the caffeine-interaction details, the sibling article covers the RCT evidence in full. For magnesium’s role in the same context of dietary patterns associated with Japanese longevity regions, see the magnesium article linked below.

---

See also: Matcha, L-Theanine, and Attention: What the Cognitive RCTs Actually Show, Magnesium in the Japanese Diet: What Cohort Research Shows.